The Impact of the International Cooperation On Familial
Hypercholesterolemia Screening and Treatment: Results from the
ScreenPro FH Project

J 2019

The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project

ČEŠKA, Richard, Gustavs LATKOVSKIS, Marat V. EZHOV, Tomáš FREIBERGER, Katarina LALIC et. al.

Základní údaje

Originální název

The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project

Autoři

ČEŠKA, Richard (garant), Gustavs LATKOVSKIS (428 Lotyšsko), Marat V. EZHOV (643 Rusko), Tomáš FREIBERGER (203 Česká republika, domácí), Katarina LALIC (688 Srbsko), Olena MITCHENKO (804 Ukrajina), Gyorgy PARAGH (348 Maďarsko), Zaneta PETRULIONIENE (440 Litva), Belma POJSKIC (70 Bosna a Hercegovina), Katarina RASLOVA (703 Slovensko), Aleksandr B. SHEK (860 Uzbekistán), Branislav VOHNOUT (703 Slovensko), Tereza ALTSCHMIEDOVÁ (203 Česká republika) a Veronika TODOROVOVÁ (203 Česká republika)

Vydání

CURRENT ATHEROSCLEROSIS REPORTS, PHILADELPHIA, CURRENT MEDICINE GROUP, 2019, 1523-3804

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.608

Kód RIV

RIV/00216224:14110/19:00110564

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1007/s11883-019-0797-3

UT WoS

000472535400003

Klíčová slova anglicky

Familial hypercholesterolemia; FH; ScreenPro FH; Evolocumab; Alirocumab; LDL-C

Štítky

14110114, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 3. 9. 2019 10:50, Mgr. Tereza Miškechová

Anotace

V originále

Purpose of ReviewFamilial hypercholesterolemia (FH) is often perceived and described as underdiagnosed and undertreated, though effective treatment of FH is available. Owing to the mentioned facts, it is ever more imperative to screen and treat FH patients. Subsequent to the identification of patients, the project focuses on the improvement of their prognoses. The ScreenPro FH project was established as a functional international network for the diagnosis, screening, and treatment of FH. Individual countries were assigned goals, e.g., to define the actual situation and available treatment. With central support, more centers and countries participated in the project. Subsequently, individual countries reported the results at the beginning and end of the project. Collected data were statistically evaluated.Recent FindingsThe increasing number of patients in databases, from 7500 in 2014 to 25,347 in 2018, demonstrates the improvement in overall effectiveness, as well as an increase in the number of centers from 70 to 252. Before all, LDL-C decreased by 41.5% and total cholesterol by 32.3%. As data from all countries and patients were not available at the time of the analysis, only those results from 10 countries and 5585 patients at the beginning of the project and at the time of writing are included.SummaryOur data are quite positive. However, our results have only limited validity. Our patients are far from the target levels of LDL-C. The situation can be improved with the introduction of new therapy, PCSK9-i, evolocumab, and alirocumab. International cooperation improved the screening of FH and finally led to an improvement in cardiovascular risk.

Citovat

ČEŠKA, Richard, Gustavs LATKOVSKIS, Marat V. EZHOV, Tomáš FREIBERGER, Katarina LALIC, Olena MITCHENKO, Gyorgy PARAGH, Zaneta PETRULIONIENE, Belma POJSKIC, Katarina RASLOVA, Aleksandr B. SHEK, Branislav VOHNOUT, Tereza ALTSCHMIEDOVÁ a Veronika TODOROVOVÁ. The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project. CURRENT ATHEROSCLEROSIS REPORTS. PHILADELPHIA: CURRENT MEDICINE GROUP, 2019, roč. 21, č. 9, s. 1-12. ISSN 1523-3804. Dostupné z: https://dx.doi.org/10.1007/s11883-019-0797-3.

@article{1551982,
   author = {Češka, Richard and Latkovskis, Gustavs and Ezhov, Marat V. and Freiberger, Tomáš and Lalic, Katarina and Mitchenko, Olena and Paragh, Gyorgy and Petrulioniene, Zaneta and Pojskic, Belma and Raslova, Katarina and Shek, Aleksandr B. and Vohnout, Branislav and Altschmiedová, Tereza and Todorovová, Veronika},
   article_location = {PHILADELPHIA},
   article_number = {9},
   doi = {http://dx.doi.org/10.1007/s11883-019-0797-3},
   keywords = {Familial hypercholesterolemia; FH; ScreenPro FH; Evolocumab; Alirocumab; LDL-C},
   language = {eng},
   issn = {1523-3804},
   journal = {CURRENT ATHEROSCLEROSIS REPORTS},
   title = {The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project},
   url = {http://dx.doi.org/10.1007/s11883-019-0797-3},
   volume = {21},
   year = {2019}
}

TY  - JOUR
ID  - 1551982
AU  - Češka, Richard - Latkovskis, Gustavs - Ezhov, Marat V. - Freiberger, Tomáš - Lalic, Katarina - Mitchenko, Olena - Paragh, Gyorgy - Petrulioniene, Zaneta - Pojskic, Belma - Raslova, Katarina - Shek, Aleksandr B. - Vohnout, Branislav - Altschmiedová, Tereza - Todorovová, Veronika
PY  - 2019
TI  - The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project
JF  - CURRENT ATHEROSCLEROSIS REPORTS
VL  - 21
IS  - 9
SP  - 1-12
EP  - 1-12
PB  - CURRENT MEDICINE GROUP
SN  - 15233804
KW  - Familial hypercholesterolemia
KW  - FH
KW  - ScreenPro FH
KW  - Evolocumab
KW  - Alirocumab
KW  - LDL-C
UR  - http://dx.doi.org/10.1007/s11883-019-0797-3
L2  - http://dx.doi.org/10.1007/s11883-019-0797-3
N2  - Purpose of ReviewFamilial hypercholesterolemia (FH) is often perceived and described as underdiagnosed and undertreated, though effective treatment of FH is available. Owing to the mentioned facts, it is ever more imperative to screen and treat FH patients. Subsequent to the identification of patients, the project focuses on the improvement of their prognoses. The ScreenPro FH project was established as a functional international network for the diagnosis, screening, and treatment of FH. Individual countries were assigned goals, e.g., to define the actual situation and available treatment. With central support, more centers and countries participated in the project. Subsequently, individual countries reported the results at the beginning and end of the project. Collected data were statistically evaluated.Recent FindingsThe increasing number of patients in databases, from 7500 in 2014 to 25,347 in 2018, demonstrates the improvement in overall effectiveness, as well as an increase in the number of centers from 70 to 252. Before all, LDL-C decreased by 41.5% and total cholesterol by 32.3%. As data from all countries and patients were not available at the time of the analysis, only those results from 10 countries and 5585 patients at the beginning of the project and at the time of writing are included.SummaryOur data are quite positive. However, our results have only limited validity. Our patients are far from the target levels of LDL-C. The situation can be improved with the introduction of new therapy, PCSK9-i, evolocumab, and alirocumab. International cooperation improved the screening of FH and finally led to an improvement in cardiovascular risk.
ER  -

ČEŠKA, Richard, Gustavs LATKOVSKIS, Marat V. EZHOV, Tomáš FREIBERGER, Katarina LALIC, Olena MITCHENKO, Gyorgy PARAGH, Zaneta PETRULIONIENE, Belma POJSKIC, Katarina RASLOVA, Aleksandr B. SHEK, Branislav VOHNOUT, Tereza ALTSCHMIEDOVÁ a Veronika TODOROVOVÁ. The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project. \textit{CURRENT ATHEROSCLEROSIS REPORTS}. PHILADELPHIA: CURRENT MEDICINE GROUP, 2019, roč.~21, č.~9, s.~1-12. ISSN~1523-3804. Dostupné z: https://dx.doi.org/10.1007/s11883-019-0797-3.

Podrobný výpis o publikaci